Company intelligence / Profile preview

SarcoMed USA

Ownership: Private
Development stage: Preclinical

Overview

SarcoMed USA’s lead program, SM001 (alidornase), is an inhaled DNase I therapy targeting chronic pulmonary inflammation in pulmonary sarcoidosis. The company completed a pre‑IND meeting with the FDA and received orphan drug status. Proof-of-concept studies are ongoing, including an open-label study using a biosimilar DNase1 in Kazakhstan. Additional indications under exploration include ARDS, idiopathic pulmonary fibrosis, and cystic fibrosis. An option exists on a no-alpha IL‑2 mutein drug for oncology indications with early clinical signals observed in Cuba.

Therapeutic areas: OncologyPulmonology
Modalities: ProteinRecombinant proteinSmall molecule
Industry: Biotech

Drug pipeline

1 asset

SM-001

Partnerships

Generium (biosimilar DNase1 supply)Roswell Park Cancer Center [collaboration on oncology asset]

Beyond the preview

Go deeper on SarcoMed USA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SarcoMed USA.

Explore the full profile